Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
Abstract The prognosis for metastatic castration‐resistant prostate cancer is unfavorable, and although Poly(ADP)‐ribose polymerase‐1 (PARP‐1) inhibitors have shown efficacy in the treatment of androgen‐receptor dependent malignancies, the limited number of options present obstacles for patients tha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.586 |